SML0141
Trilostane
≥98% (HPLC)
Sinônimo(s):
(4α,5α,17β)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Fórmula empírica (Notação de Hill):
C20H27NO3
Número CAS:
Peso molecular:
329.43
Número CE:
Número MDL:
Código UNSPSC:
51111800
ID de substância PubChem:
NACRES:
NA.77
Produtos recomendados
Ensaio
≥98% (HPLC)
Formulário
powder
cor
white to tan
solubilidade
DMSO: ≥17 mg/mL
temperatura de armazenamento
2-8°C
cadeia de caracteres SMILES
C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(O)=C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O
InChI
1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1
chave InChI
KVJXBPDAXMEYOA-CXANFOAXSA-N
Informações sobre genes
human ... HSD3B2(3284)
Categorias relacionadas
Descrição geral
Trilostane inhibits the production of adrenal steroids, such as cortisol and aldosterone. It is used to treat aldosteronism.
Aplicação
Trilostane has been used to evaluate its capability to regulate the sex-dependent differences in the lipopolysaccharide (LPS)-induced inflammatory responses of astrocytes.
Trilostane was used to inhibit the activity of 3β-hydroxysteroid dehydrogenase in mouse ovary.
Ações bioquímicas/fisiológicas
Inhibitor of 3 β-hydroxysteroid dehydrogenase
Trilostane is an inhibitor of 3 β-hydroxysteroid dehydrogenase (3-β-HSD or delta 5-delta 4-isomerase), an essential enzyme for the biosynthesis of all classes of hormonal steroids. It has been used in the treatment of Cushing′s syndrome for stopping the production of cortisol, and is currently approved for dogs in the US, but is still a human drug in the UK and other countries. It is being investigated as a possible treatment for both breast cancer and prostate cancer to prevent the synthesis of estrogens and androgens from endogenous precursors. It has also been used to inhibit endogenous production of progesterone in research studies.
Características e benefícios
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Palavra indicadora
Warning
Frases de perigo
Declarações de precaução
Classificações de perigo
Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2
Código de classe de armazenamento
11 - Combustible Solids
Classe de risco de água (WGK)
WGK 3
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Escolha uma das versões mais recentes:
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Nyssa J Reine
Clinical techniques in small animal practice, 22(1), 18-25 (2007-06-05)
Pituitary-dependent hyperadrenocorticism is a common endocrine disorder in dogs in the United States. Once a diagnosis is established, a decision must be made whether or not to pursue treatment, and if so, which medication to use. Historically, mitotane (Lysodren, o,p'-DDD
P M Y Smets et al.
Journal of veterinary internal medicine, 26(3), 565-574 (2012-04-03)
Systemic hypertension and proteinuria are frequent complications in dogs with Cushing's syndrome and do not always resolve after treatment of hypercortisolism. Therefore, dogs with Cushing's syndrome may be at risk for renal dysfunction before and after treatment. To assess renal
Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism
Neiger R , et al.
The Veterinary Record, 150(26), 799-803 (2002)
Edward C Feldman
Journal of the American Veterinary Medical Association, 238(11), 1441-1451 (2011-06-02)
To evaluate effectiveness and incidence of adverse reactions to twice-daily lower-dose oral administration of trilostane in the treatment of dogs with naturally occurring hyperadrenocorticism (NOH). Clinical trial. 47 dogs with NOH. 47 dogs were treated orally with trilostane (0.21 to
K-D Cho et al.
Journal of veterinary internal medicine, 27(1), 91-98 (2012-11-22)
Trilostane is commonly used to treat pituitary-dependent hyperadrenocorticism (PDH) in dogs. There are differing opinions regarding the dose and frequency of trilostane administration in dogs with PDH. To compare the efficacy of 2 trilostane protocols in the treatment of dogs
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica